CLINICAL_TRIALS
trial_result
· 2025-02-10
Clinical Trial Update: A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma [Phase 1]
Summary
A Phase 1 study evaluating intratumoral MTX110 in patients with recurrent glioblastoma has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Biodexa Pharmaceuticals | Conditions: Recurrent Glioblastoma | Phase 1 | Status: TERMINATED